ELVN Benjamin Hohl sells $67K worth of shares
Aug 30, 2025, 4:37 AM
0.00%
What does ELVN do
Enliven Therapeutics, a clinical stage precision oncology company based in Boulder, Colorado, went public on March 12, 2020. It is developing ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 mutations.
Benjamin Hohl sold 3,250 shares of ELVN on 27 August at $20.63 per share, worth a total of $67K. They now own 23,000 ELVN shares, or a 12% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.